Please login to the form below

Not currently logged in
Email:
Password:

IMI

This page shows the latest IMI news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Europe launches antimicrobial research ‘Accelerator’. A new Antimicrobial Resistance (AMR) Accelerator Programme has been unveiled by the EU and pharma-funded Innovative Medicines Initiative (IMI). ... Meanwhile the topics on digital health and the

Latest news

More from news
Approximately 14 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    She made major scientific contributions to neuroscience R&D within the pharmaceutical industry at GlaxoSmithkline, and also championed the vision for the Stevenage Bioscience Catalyst and theEuropean Innovative Medicines Initiative (IMI).

  • A quest for innovative solutions A quest for innovative solutions

    The innovative Medicines Initiative (IMI), with 5.3bn invested in 90 projects, is a barometer of the industry’s deep dive into technology at a time when ageing populations with multiple

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    There are a number of collaborations we have with biotech companies in Europe, but regarding the IMI collaboration, it is too early yet for discussion.”. ... Several other companies are signed up to the IMI's efforts in AMR, including GlaxoSmithKline,

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    of working with local academics, while the Innovative Medicines Initiative (IMI) is bringing EFPIA members together with academics and biotechs to research major public health problems.

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    clinical data or the EC-backed Innovative Medicines Initiative (IMI).

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Innovative Medicines Initiative appoints executive director Innovative Medicines Initiative appoints executive director

    Pierre Meulien joins from Genome Canada . Innovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September. ... Pierre Meulien's invaluable experience will help IMI deliver on its ambitious objectives.”.

  • IMI picks Ipsen's Marc de Garidel to chair governing board IMI picks Ipsen's Marc de Garidel to chair governing board

    Its second-phase IMI 2 programme aims to develop next generation vaccines, medicines and treatments, such as new antibiotics. ... I am confident that his decades of experience working in the pharmaceutical sector will prove invaluable to IMI.”.

  • IMI appoints new chair of scientific committee IMI appoints new chair of scientific committee

    Prof Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI). ... Finally, there is huge potential to expand the principles underlying IMI to the rest of the world.”.

  • Hans Lennernas joins board of CMO Recipharm Hans Lennernas joins board of CMO Recipharm

    Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics